

Junyun Lai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/423216/publications.pdf>

Version: 2024-02-01

15
papers

940
citations

840776

11
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

1532
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell Model. <i>Cancers</i> , 2021, 13, 867.	3.7	9
2	Characterization and Establishment of a Novel EBV Strain Simultaneously Associated With Nasopharyngeal Carcinoma and B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 626659.	2.8	2
3	Cellular networks controlling T cell persistence in adoptive cell therapy. <i>Nature Reviews Immunology</i> , 2021, 21, 769-784.	22.7	83
4	CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. <i>Nature Communications</i> , 2021, 12, 3236.	12.8	99
5	MAIT cells regulate NK cell-mediated tumor immunity. <i>Nature Communications</i> , 2021, 12, 4746.	12.8	45
6	Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis. <i>Cancer Research</i> , 2021, 81, 5803-5805.	0.9	4
7	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. <i>Molecular Therapy</i> , 2020, 28, 2379-2393.	8.2	49
8	Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. <i>Nature Immunology</i> , 2020, 21, 914-926.	14.5	114
9	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 487-504.	7.0	355
10	Switching on the green light for chimeric antigen receptor T cell therapy. <i>Clinical and Translational Immunology</i> , 2019, 8, e1046.	3.8	11
11	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4 ⁺ Foxp3 ⁺ Cell-Mediated Modulation of CD103 ⁺ Dendritic Cells. <i>Cancer Immunology Research</i> , 2018, 6, 1069-1081.	3.4	67
12	TCR-like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus-transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants. <i>Scientific Reports</i> , 2017, 7, 9923.	3.3	14
13	Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities. <i>Blood</i> , 2016, 128, 1396-1407.	1.4	17
14	The NLRP3 inflammasome affects DNA damage responses after oxidative and genotoxic stress in dendritic cells. <i>European Journal of Immunology</i> , 2013, 43, 2126-2137.	2.9	52
15	Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies. <i>Scientific Reports</i> , 2013, 3, 3232.	3.3	19